Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

993
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

7.5K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
7.5K
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

807
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
807

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Long-term Volumetric and Radiological Changes of COVID-19 on Lung Anatomy: A Quantitative Assessment.

Current medical imaging·2025
Same author

Green/eco-friendly electronic approaches: Analysis of optoelectronic applications of cellulose-supported composite hydrogels.

International journal of biological macromolecules·2025
Same author

VARIATIONS OF SERUM DEHYDROEPIANDROSTERONE-SULPHATE (DHEAS) LEVEL WITH PREGNANCY, FERTILITY, ABORTION, OVARIAN RESERVE AND ENDOTHELIAL FUNCTIONS.

Acta endocrinologica (Bucharest, Romania : 2005)·2024
Same author

A multicenter multinational study to evaluate different aspects of the relationship between MS and pregnancy.

Multiple sclerosis and related disorders·2024
Same author

Does anxiety, depression, and sleep levels affect the quality of life in patients diagnosed with multiple sclerosis?

European review for medical and pharmacological sciences·2024
Same author

Investigation of social appearance anxiety and self-esteem in individuals planned for aesthetic rhinoplasty.

European review for medical and pharmacological sciences·2024

Related Experiment Video

Updated: May 1, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

8.3K

Pantoprazole may improve beta cell function and diabetes mellitus.

F Inci1, M Atmaca, M Ozturk

  • 1Department of Internal Medicine, University of Yuzuncu Yil, Van, Turkey.

Journal of Endocrinological Investigation
|April 1, 2014
PubMed
Summary

Proton pump inhibitors like pantoprazole may improve pancreatic beta cell function and lower blood sugar levels in patients with and without type 2 diabetes. This suggests potential benefits of PPIs in diabetes management.

More Related Videos

High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds
12:32

High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds

Published on: January 23, 2018

10.7K
A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
09:35

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

Published on: July 16, 2016

10.4K

Related Experiment Videos

Last Updated: May 1, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

8.3K
High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds
12:32

High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds

Published on: January 23, 2018

10.7K
A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
09:35

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform

Published on: July 16, 2016

10.4K

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Proton pump inhibitors (PPIs) suppress gastric acid, leading to hypergastrinemia.
  • Elevated gastrin levels can stimulate pancreatic beta cells, mimicking incretin effects.
  • Previous studies suggest PPIs may reduce glycosylated hemoglobin (HbA1c).

Purpose of the Study:

  • To investigate the impact of pantoprazole on beta cell function in diabetic and non-diabetic individuals.
  • To assess changes in glycemic control and beta cell markers during pantoprazole treatment.

Main Methods:

  • A 12-week study involving 79 male patients (38 non-diabetic, 41 type-2 diabetic on metformin).
  • Pantoprazole 40 mg/day was administered.
  • Measurements included fasting plasma glucose (FPG), HbA1c, fasting insulin, HOMA-B (beta cell function), proinsulin, and c-peptide.

Main Results:

  • In non-diabetic patients, pantoprazole decreased FPG and increased c-peptide and HOMA-B.
  • In type 2 diabetic patients, pantoprazole reduced FPG, HbA1c, and weight, while increasing HOMA-B, c-peptide, and proinsulin.
  • Beta cell function correlated positively with c-peptide and insulin, and inversely with FBG and HbA1c.

Conclusions:

  • Pantoprazole administration appears to enhance beta cell function and improve glycemic control (HbA1c, FPG).
  • The study indicates pantoprazole may positively influence beta cell function markers like HOMA-B, c-peptide, and proinsulin.
  • Given the role of beta cell dysfunction in type 2 diabetes, PPIs warrant consideration as a potential adjunctive therapy.